FDA clears genetically engineered TIL therapy for solid tumour trials
Drug Discovery World
SEPTEMBER 3, 2024
The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for advanced solid tumour patients. GT201 is designed to boost T cell survival and function by expressing a vital membrane-bound cytokine complex.
Let's personalize your content